MADRIGAL PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Jul 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 30, 2026
MDGL$432.79+8.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
| ExhibitNumber · Exhibit Description · Incorporated by Reference · FiledHerewith | |||||
|---|---|---|---|---|---|
| 10.1* | Madrigal Pharmaceuticals, Inc. 2026 Stock Plan | Form 8-K (Exhibit 10.1) | 6/17/2026 | 001-33277 | |
| 10.2* | Form of Non-Qualified Stock Option Agreement | Form S-8 (99.2) | 6/17/2026 | 001-33277 | |
| 10.3* | Form of Non-Qualified Stock Option Agreement (Non-Employee Director) | Form S-8 (99.3) | 6/17/2026 | 001-33277 | |
| 10.4* | Form of Restricted Stock Unit Award Agreement (Non-Section 16 Officer) | Form S-8 (99.4) | 6/17/2026 | 001-33277 | |
| 10.5* | Form of Restricted Stock Unit Award Agreement (Section 16 Officer) | Form S-8 (99.5) | 6/17/2026 | 001-33277 | |
| 10.6* | Form of Restricted Stock Unit Award Agreement (Non-Employee Director) | Form S-8 (99.6) | 6/17/2026 | 001-33277 | |
| 10.7* | Form of Performance-Based Restricted Stock Unit Award Agreement | Form S-8 (99.7) | 6/17/2026 | 001-33277 | |
| 10.8* | Form of Incentive Stock Option Agreement | Form S-8 (99.8) | 6/17/2026 | 001-33277 | |
| 10.9* | Madrigal Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan | Form 8-K (Exhibit 10.2) | 6/17/2026 | 001-33277 | |
| 10.10* | Madrigal Pharmaceuticals, Inc. Nonqualified Deferred Compensation Plan | Form 8-K (Exhibit 10.3) | 6/17/2026 | 001-33277 | |
| 10.11*# | Consulting Agreement, dated as of June 17, 2026, by and between the Registrant and Rebecca Taub, M.D. | X | |||
| 10.12† | Third Amendment Agreement, dated as of May 4, 2026, among the Registrant, certain subsidiaries of the Registrant, certain funds managed by Blue Owl Capital Corporation and LSI Financing LLC. | X | |||
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1** | Certifications of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101.INS | Inline XBRL Instance Document. | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | X |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | X |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | X |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | X |
| 104 | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set. |
- Indicates a management contract, compensatory plan or arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.